CME/CE Accredited Session
Non-CME/CE Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
Alcohol in the Anxious Age of COVID: Medications Against Self-Medications
Petros Levounis, MD, MA
Alcohol use frequently co-occurs with anxiety disorders, especially during the highly anxiety-provoking circumstances of the current pandemic. People increasingly self-medicate their stress with alcohol, sometimes leading to frank alcohol use disorder. Despite alcohol’s legal status and social acceptability in many countries, it remains a potentially dangerous, toxic substance. Withdrawal from alcohol can be fatal, and medically managed withdrawal is often necessary to ensure patient safety. In this presentation, we will describe the fundamental pharmacology and acute presentations of alcohol use disorder and discuss counseling approaches. We will then explore the clinical aspects of the three FDA-approved medications for its treatment: disulfiram, naltrexone, and acamprosate. We will conclude with some novel ideas about future directions in the pharmacotherapy of alcohol use disorders.
Professor and Chair, Department of Psychiatry, Rutgers New Jersey Medical School, Chief of Service, University Hospital, Newark, NJ
Managing Obesity in Primary Care Practice
Fatima Cody Stanford, MD, MPH, MPA, FAAP, FACP, FTOS
Obesity is the most prevalent chronic disease of the modern era in the U.S. and around the world, affecting both the adult and pediatric population. Although many believe that helping patients to achieve a healthy weight is of minimal complexity, weight regulation and management is a challenging endeavor. In this talk, the faculty will explore the complexities of obesity and offer a range of strategies (behavioral, therapeutic, and surgical) to help you in the quest to address overweight and obesity in your practice.
Obesity Medicine Physician Scientist, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Eugene E. Wright, MD | Kris Vijay, Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA
The objectives of the program are to:
Consulting Associate, Department of Medicine, Department of Community and Family Medicine, Duke Southern Regional Area Health Education Center (AHEC), Fayetteville, North Carolina
(Krishnaswami Vijayaraghavan, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA)
Medical Director, CHF, Abrazo Arizona Heart Hospital and Abrazo Health Network, Clinical Professor of Medicine, University of Arizona, Adjunct Professor of Medicine, Midwestern University, Glendale, Arizona, Associate Editor, Journal of Clinical Lipidology, Past Governor, ACC Arizona, Founding Member and Past President, Cardiorenal Society of America (CRSA), Founding member and President, Twinepidemic, Inc, President, Innovative Cardiometabolic Center
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
Paul Sutej, MD
Sponsored by AbbVie
Philip Schoenfeld, MD, MSEd, MSc
This activity will provide an evidence-based approach to the diagnosis and management of irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.
Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI
Supported by Allergan and Ironwood Pharmaceuticals, Inc. Salix Pharmaceuticals
Ted Okerson, MD, FACP, FACE
Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.
Sponsored by AstraZeneca Pharmaceuticals, LP
Carlos Campos, MD, MPH, CDE
The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.
Clinical Adjunct Professor, UT Health San Antonio, San Antonio, TX
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LL
Know the Facts and Save a Life: Detection and Management of Intracranial Aneurysm in Primary Care
Christopher S. Ogilvy, MD
One in fifty people in the U.S. has an unruptured brain aneurysm, and one ruptures every 18 minutes. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death. Complicating matters more, many of the symptoms are associated with other less dangerous conditions, such as influenza or stress. This session will describe the importance of early detection, since brain aneurysms are treatable via proper identification, and will highlight risk factors and populations who are most vulnerable. Faculty will also review treatment options for clinicians to recognize or use in practice.
Director, Endovascular and Operative Neurovascular Surgery, BIDMC Brain Aneurysm Institute, Professor of Neurosurgery, Harvard Medical School, Boston, MA
Michael Ledet, MD
In a presentation with Dr. Ledet, learn about the pivotal clinical data and a pilot study that evaluated the next-dose transition from a treatment to this treatment option
Medical Director, Southeast Regional Center for Sleep/Wake Disorders at Springhill Medical Center
Dr. Ledet has been the Medical Director of Southeast Regional Center for Sleep/Wake Disorders at Springhill Medical Center for the past 30 years in Mobile, Alabama and is board certified in Family Medicine, Sleep Medicine, and Lipidology.
Sponsored by Eisai Inc.
End of Life Care Planning: Considerations in The Time of COVID-19
Lee A. Lindquist, MD, MPH, MBA
With the COVID-19 Pandemic, older adults have experienced severe illness, increased hospitalizations, and mortality at alarming rates. Nursing homes and long-term care retirement communities emerged as COVID-19 hotspots with rampant outbreaks. Every older adult diagnosed with or exposed to COVID-19 have realized the potential ramifications. Providers have been at the forefront of mediating these decisions. Dr. Lindquist will discuss how long-term care and end-of-life planning has been impacted by COVID-19. Utilizing real-world examples with older adults and experiences in home-based and nursing home care, Dr. Lindquist will showcase how to prepare older adults and their loved ones for the consequences of COVID-19.
Chief of Geratrics, Northwestern University Feinberg School of Medicine, Chicago, IL
Supported by Commercial Supporter here
Evaluation and Treatment of Hip, Knee, and Back Pain in the Outpatient Setting
Stephen N. Henry, DO, MS
Hip, knee, and back pain are common complaints in the outpatient setting. It is critical for primary care providers to develop an evidence-based systematic approach to address these complaints. This presentation will improve familiarity with anatomy of the hip, knee, and back through a case-based approach. Learners will be able to generate differential diagnoses for pain in the aforementioned regions and determine appropriate imaging studies using ACR
Supported by Commercial Supporter here
*This is a hypothetical case and not an actual patient
Uncover the cause of the patient's symptoms in this virtual case study and consider if this could apply to any patients you manage.
Marina Magrey, MD
This webinar will educate primary care physicians on screening tools for assessment of axial spondyloarthritis, including referral strategies presented by the Assessment of SpondyloArthritis international Society (ASAS) and the Prevalence of Axial Spondyloarthritis (PROSpA) to help inform decisions on appropriate referrals to rheumatologists. This is the fifth chapter of a series of videos exploring early recognition of axSpA.
Join us for a live webinar with Dr. Danve and Dr. Magrey on May 15.
Case Western Reserve University School of Medicine, MetroHealth Medical Center
Sponsored by Novartis
Curbside Cardiology Consult: Peripheral Artery Disease and Heart Failure
Ty J. Gluckman, MD, FACC, FAHA | Alison L. Bailey, MD, FACC, FAACVPR
Heart failure is a global pandemic that continues to increase in prevalence. Despite the availability of established and novel therapies, mortality and morbidity in heart failure remains high. Join us for this overview of heart failure classification and pathophysiology, the evidence base supporting various treatments, and current guideline recommendations.
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS),, Providence Heart Institute, Providence St. Joseph Health, Portland, OR
Governor, Tennessee Chapter,, American College of Cardiology, Washington, DC
Supported by Commercial Supporter here
Top COVID Questions: Mental Health and Gastroenterology
Shirah Vollmer, MD
Session Overview to Come
Clinical Professor of Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA
Supported by Commercial Supporter here
Evaluate when the guidelines recommend GLP-1 RA use for T2D treatment. Review the glucose-dependent mechanism of action, safety, and dosing of a once-weekly GLP-1 RA. Discuss the efficacy and safety data from pivotal T2D glycemic control trials and from the cardiovascular outcomes trial
Sponsored by Novo Nordisk Inc.
Jeffrey Teckman, MD
This educational program will provide a practical overview of common liver diseases which may be encountered in Primary Care, such as NAFLD and NASH. Differentiation of less common hepatic pathology, such as alpha-1 antitrypsin deficiency, will be reviewed.
Interim Chairman, Department of Pediatrics, Drs. Patricia & James Monteleone Endowed Chair in Pediatric Gastroenterology, Professor of Pediatrics, Professor of Biochemistry and Molecular Biology, Director of Pediatric Gastroenterology and Hepatology, Saint Louis University School of Medicine
Sponsored by Takeda Pharmaceuticals U.S.A., Inc.
Nutritional and Pharmacological Approach to IBS-D and its Masqueraders
William D. Chey, MD, FACG, AGAF, FACP, RFF | Kate Scarlata, MPH, DRN | Neilanjan Nandi, MD, FACP
This symposium will provide an overview of practical diagnostic and treatment considerations for managing patients with IBS-D in the primary care setting. Diagnostic approaches for IBS-D will be reviewed in the context of conditions that commonly mimic symptoms of the disorder. Participants will learn about the latest evidence based treatment strategies for IBS-D, including nutritional approaches, behavioral therapies, and conventional and newer pharmacologic therapies.
Director, GI Physiology Lab, Director, Nutrition & Lifestyle Program, Michigan Medicine, Ann Arbor, MI
For a Digestive Peace of Mind, Medway, MA
Associate Professor of Clinical Medicine, Inflammatory Bowel Diseases Center, University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia, PA
The Continuum of Heart Failure
Pam R. Taub, MD, FACC
The objective of this program is to discuss the pathophysiology, disease burden, and management of heart failure (HF). The program will present data on HF prevalence and health outcomes, review the implications of type 2 diabetes as a common comorbidity, and provide guidance on diagnosing HF. It will conclude with a brief overview of current treatment options for HF.
Associate Professor of Medicine, UC San Diego Health System, San Diego, California
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC